Proteomic maps of the cancer-associated infectious agents

Journal of Proteome Research

Volumn 4, Issue 4, 2005, Pages 1171-1180

  Srivastava, Sudhir ^a,b   Verma, Mukesh ^a   Gopal Srivastava, Rashmi ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Acetylation; Apoptosis; Biomarkers; Chromatin; Early Detection; Epigenetics; Epigenome; Gene therapy; Infectious agents; Matrix assisted laser capture ionization desorption mass spectrometry (MALDI MS); Methylation; Post translational modifications (PTM)

Indexed keywords

CANCER VACCINE; SMALL INTERFERING RNA;

ACETYLATION; APOPTOSIS; BRAIN CANCER; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CANCER PREVENTION; CARCINOGENESIS; CHROMATIN; COLON CANCER; EARLY DIAGNOSIS; EPIGENETICS; EPSTEIN BARR VIRUS; GENE THERAPY; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION; INFORMATION CENTER; JC VIRUS; KAPOSI SARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; RISK ASSESSMENT; RNA TRANSLATION; UTERINE CERVIX CANCER; WART VIRUS;

ANIMALS; COMMUNICABLE DISEASES; HUMANS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOME; TUMOR MARKERS, BIOLOGICAL; VIRAL PROTEINS;

EID: 23944452883     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr050017m     Document Type: Review

References (109)

1. O'Brien, K.; Cokkinides, V.; Jemal, A, Cardinez, C. J.; Murray, T.; Samuels, A.; Ward, E.; Thun, M. J. Cancer statistics for Hispanics. Cancer J. Clin. 2003, 53, 208-226.
2. Rosenblatt, K. A.; Carter J. J.; Iwasaki, L. M.; Galloway, D. A.; Stanford, J. L. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 763-768.
3. Gencer, S.; Salepci, T.; Ozer, S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. J. Infect. 2003, 47, 65-72.
4. Somech, R.; Amariglio, N.; Spirer, Z.; Rechavi, G. Genetic predisposition to infectious pathogens: a review of less familiar variants. Pediatr. Infect. Dis. J. 2003, 22, 457-461.
5. Kellam, P. Microarray gene expression database: progress towards an international repository of gene expression data. Genome Biol. 2001, 2, 4011.
6. Verma, M.; Srivastava, S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 2003, 163, 72-84; discussion 264-266.
7. Verma, M.; Lambert, P. F.; Srivastava, S. K. Meeting highlights: National Cancer Institute workshop on molecular signatures of infectious agents. Dis. Markers 2001, 17, 191-201.
8. Reiss, K.; Khalili, K. Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene 2003, 22, 6517-6523.
9. Lavia, P.; Mileo, A. M.; Giordano, A.; Paggi, M. G. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene 2003, 22, 6508-6516.
10. McCormick, F. Cancer-Specific Viruses and the Development of ONYX-015. Cancer Biol. Ther. 2003, 2, S157-60.
11. Lucas, A.; Kremer, EJ, Hemmi S, Luis J, Vignon F, Lazennec G. Comparative transductions of breast cancer cells by three DNA viruses. Biochem. Biophys. Res. Commun. 2003, 309, 1011-1016.
12. Pealer, L. N.; Marfin, A. A.; Petersen L. R.; Lanciotti, R. S.; Page, P. L.; Stramer S. L.; Stobierski, M. G.; Signs, K.; Newman, B.; Kapoor, H.; Goodman, J. L.; Chamberland, M. E. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 2003, 349, 1236-1245.
13. Butz, K.; Ristriani, T.; Hengstermann A.; Denk, C.; Scheffner, M.; Hoppe-Seyler, F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22, 5938-5945.
14. Poirier, F.; Pontet, M.; Labas, V.; le Caer, J. P.; Sghiouar-Imam, N.; Raphael, M.; Caron, M.; Joubert-Caron, R. Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: protein pattern changes following treatment with 5′-azycytidine. Electrophoresis 2001, 22, 1867-1877.
15. Carry, R. F.; Dash, S. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 2003, 307, 255-265.
16. Korth, M. J.; Katze, M. G. Unlocking the mysteries of virus-host interactions: does functional genomics hold the key? Ann. N. Y. Acad. Sci. 2002, 975, 160-168.
17. Tang, H.; Peng, T.; Wong-Staal, F. Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV. Curr Opin Pharmacol. 2002, 2, 541-547.
18. Houghton, R. L.; Lodes, M. J.; Dillon, D. C.; Reynolds, L. D.; Day, C. H.; McNeill, P. D.; Hendrickson, R. C.; Skeiky, Y. A.; Sampaio, D. P.; Badaro, R.; Lyashchenko, K. P.; Reed, S. G. Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin. Diagn. Lab. Immunol. 2002, 9, 883-891.
19. Fuchigami, T.; Misumi, S.; Takamune, N.; Takahashi, I.; Takama, M.; Shoji, S. Acid-labile formylation of amino terminal proline of human immunodeficiency virus type 1 p24(gag) was found ty proteomics using two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Biochem. Biophys. Res. Commun. 2002, 293, 1107-1113.
20. Chaiken, I. Revealing and utilizing receptor recognition mechanisms in a high-throughput world. J. Cell Biochem. Suppl. 2001, 57, 126-135.
21. Goldfarb, M. Analysis of antibody to milk proteins in HIV positive/negative sera using two-dimensional electrophoresis, western blot and immunoassay. Proteomics 2001, 1, 721-725.
22. Pamulok, M.; Blind, M.; Mayer, G. Intramers as promising new tools in functional proteomics. Chem. Biol. 2001, 8, 931-939.
23. Loo, J. A.; Dejohn, D. E.; Du, P.; Stevenson, T. I.; Ogorzalek Loo, F. R. Application of mass spectrometry for target identification and characterization. Med. Res. Reu. 1999, 19, 307-319.
24. Verma, M. Viral genes and methylation. Ann. N. Y. Acad. Sci. 2003, 583, 170-180.
25. Yoshioka, M.; Kikuta, H.; Ishiguro, N.; Endo, R.; Kobayashi, K. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome. J. Med. Virol. 2003, 70, 410-419.
26. Barth, S.; Liss, M.; Voss, M. D.; Dobner, T.; Fischer, U.; Meister, G.; Grasser, F. A. Epstein-Barr virus nuclear antigen 2 binds via its methylated arginine-glycine repeat to the survival motor neuron protein. J. Virol. 2003, 77, 5008-5013.
27. Osawa, T.; Chong, J. M.; Sudo, M.; Sakuma, K.; Uozaki, H.; Shibahara, J.; Nagai, H.; Funata, N.; Fukayama, M., Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn. J. Cancer. Res. 2002, 93, 1195-1200.
28. Paulson, E. J.; Fingeroth, J. D.; Yates, J. L.; Speck, S. H. Methylation of the EBV genome and establishment of restricted latency in low-passage EBV-infected 293 epithelial cells. Virology 2002, 299, 109-121.
29. Akhtar, M.; Cheng, Y.; Magno, R. M.; Ashktorab, H.; Smoot, D. T.; Meltzer, S. J.; Wilson, K. T. Promoter methylation regulates helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 2001, 61, 2399-2403.
30. Chan, A. O.; Lam, S. K.; Wong, B. C.; Yuen, M. F.; Yeung, Y. H.; Hui, W. M.; Rashid, A.; Kwong, Y. L. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52, 502-506.
31. Xiao, S.; Ran Z. Recent advances in molecular biology of gastric carcinogenesis. Chin. Med. J. (Engl) 2003, 116, 3-4.
32. Genther, S. M.; Sterling, S.; Duensing, S.; Munger, K.; Sattler, C.; Limbert, P. F. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 2003, 77, 2832-2842.
33. Middleton, K.; Peh, W.; Southern, S.; Griffin, H.; Sotlar, K.; Nakahara, T.; El-Sherif, A.; Morris, L.; Seth, R.; Hibma, M.; Jenkins, D.; Lambert, P.; Coleman, N.; Doorbar, J. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J. Virol. 2003, 77, 10186-10201.
34. Virma, M.; Srivastava, S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002, 3, 755-763.
35. Diaz, J. J.; Giraud, S.; Greco, A. Alteration of ribosomal protein maps in herpes simplex virus type 1 infection. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2002, 771, 237-249.
36. Greco, A.; Bienvenut, W.; Sanchez, J. C.; Kindbeiter, K.; Hochstrasser, D.; Madjar, J. J.; Diaz, J. J. Identification of ribosome-associated viral and cellular basic proteins during the course of infection with herpes simplex virus type 1. Proteomics 2001, 1, 545-549.
37. Greco, A.; Bausch, N.; Coute, Y.; Diaz, J. J. Characterization by two-dimensional gel electrophoresis of host proteins whose synthesis is sustained or stimulated during the course of herpes simplex virus type 1 infection. Electrophoresis 2000, 21, 2522-2530.
38. Laurent, A. M.; Madjar, J. J.; Greco, A. Translational control of viral and host protein synthesis during the course of herpes simplex virus type 1 infection: evidence that initiation of translation is the limiting step. J. Gen. Virol. 1998, 79, 2765-2775.
39. Lee, K. M.; Lee, D. S.; Yang, J. M.; Ahn, B. M.; Lee, E. H.; Yoo, J. Y. Kim, Y. J.; Chung, I. S.; Sun, H. S.; Park, D. H. Effect of Helicobacter pylori on Gastric Epithelial Cell Kinetics and Expression of Apoptosis-related Proteins in Gastric Carcinogenesis. Korean J. Gastroenterol. 2003, 42, 12-19.
40. Juttner, S.; Cramer, T.; Wessler, S.; et al. Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cell Microbiol. 2003, 5, 821-834.
41. Jiang, X. H.; Wong, B. C. Cyclooxygenase-2 inhibition and gastric cancer. Curr. Pharm. Des. 2003, 9, 2281-2288.
42. Zhang, G. X.; Zhao, Z. Q.; Gu, Y. H.; Xu, S. F.; Zhang, H. J. Coordinated expression of c-Myc and telomerase activity in Helicobacter pylori infected gastric diseases. Zhonghua Nei Ke Za Zhi 2003, 42, 618-620.
43. Kang, G. H.; Lee, H. J.; Hwang, K. S.; Lee, S.; Kim, J. H.; Kim, J. S. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am. J. Pathol. 2003, 163, 1551-1556.
44. Basset, C.; Holton, J.; Ricci, C.; Gatta, L.; Tampieri, A.; Perna, F.; Miglioli, M.; Vaira, D. Review article: diagnosis and treatment of Helicobacter: a 2002 updated review. Aliment Pharmacol. Ther. 2003, 17, 89-97.
45. Abdel-Rahim, A. Y. Parasitic infections and hepatic neoplasia. Dig. Dis. 2001, 19, 288-291.
46. Pisani, P.; Parkin, D. M.; Munoz, N.; Ferlay, J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 1997, 6, 387-400.
47. Gentile, J. M. Schistosome related cancers: a possible role for genotoxins. Environ. Mutagen. 1985, 7, 775-785.
48. Neuhierl, B.; Feederle, R.; Hammerschmidt, W.; Delecluse, H. J. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 15036-15041.
49. Memar, O. M.; Rady, P. L.; Tyring, S. K. Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions. J. Mol. Med. 1995, 73, 603-9.
50. Stebbing, J.; Gazzard, B.; Flore, O.; Thomas, C.; Benlahrech, A.; Mandalia, S.; Bower, M.; Gotch, F. Patterson S. Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. AIDS 2003, 17, 1998-2000.
51. Noy, A. Update in Kaposi sarcoma. Curr. Opin. Oncol. 2003, 15, 379-381.
52. Poynard, T.; Yuen, M.; Ratziu, V.; Lai, C. L. Viral hepatitis C. Lancet 2003, 362, 2095-2100.
53. Tsutsumi, T.; Suzuki, T.; Moriya, K.; Shintani, Y.; Fujie, H.; Miyoshi, H.; Matsuura, Y.; Koike, K.; Miyamura, T. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 2003, 38, 820-828.
54. Li, Q.; Dong, C.; Wang, J.; Che, Y.; Jiang, L.; Wang, J.; Sun, M.; Wang, L.; Huang, J.; Ren, D. Induction of hepatitis C virus-specific humoral and cellular immune responses in mice and rhesus by artificial multiple epitopes sequence. Viral. Immunol. 2003, 16, 321-333.
55. Kyono, K.; Miyashiro, M.; Taguchi, I. Characterization of ATPase activity of a hepatitis C virus NS3 helicase domain, and analysis involving mercuric reagents. J. Biochem. (Tokyo) 2003, 134, 505-511.
56. Shin, B. K.; Wang, H.; Hanash, S. Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7, 407-413.
57. Ichiba, T.; Teshima, T.; Kuick, R.; Misek, D. E.; Liu, C.; Takada, Y.; Maeda, Y.; Reddy, P.; Williams, D. L.; Hanash, S. M.; Ferrara, J. L. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood 2003, 102, 763-71.
58. Naour, F. L.; Brichory, F.; Beretta, L.; Hanash, S. M. Identification of tumor-associated antigens using proteomics. Technol. Cancer Res. Treat. 2002, 1, 257-262.
59. Hanash, S. Harnessing immunity for cancer marker discovery. Nat. Biotechnol. 2003, 21, 37-38.
60. Hanash, S.; Brichory, F.; Beer, D. A proteomic approach to the identification of lung cancer markers. Dis. Markers 2001, 17, 295-300.
61. Thomas, J. J.; Bakhtiar, R.; Siuzdak, G. Mass spectrometry in viral proteomics. Acc. Chem. Res. 2000, 33, 179-187.
62. Wulfkuhle, J. D.; Paweletz, C. P.; Steeg, P. S.; Petricoin, E. F. 3rd.; Liotta, L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol. 2003, 532, 59-68.
63. Fetsch, P. A.; Simone, N. L.; Bryant-Greenwood, P. K.; Marincola, F. M.; Filie, A. C.; Petricoin, E. F.; Liotta, L. A.; Abati, A. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am. J. Clin. Pathol. 2002, 118, 870-876.
64. Ardekani, A. M.; Liotta, L. A.; Petricoin, E. F. 3rd Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert. Rev. Mol. Diagn. 2002, 2, 312-320.
65. Paweletz, C. P.; Trock, B.; Pennanen, M.; Tsangaris, T.; Magnant, C.; Liotta, L. A.; Petricoin, E. F. 3rd Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 2001, 17, 301-307.
66. Margalith, M.; Chatlynne, L. G.; Fuchs, E.; et al. Human herpes-virus 8 infection among various population groups in southern Israel. J. Acquir. Immune. Defic. Syndr. 2003, 34, 500-505.
67. Du, W.; Xu, Z.; Ma, X.; Song, L.; Schneider E. M. Biochip as a potential platform of serological interferon α2b antibody assay. J. Biotechnol 2003, 106, 87-100.
68. Vazquez-Corzo, S.; Trejo-Becerril, C.; Cruz-Valdez, A.; Hernandez-Nevarez, P.; Esquivel-Guadarrama, R.; Gutierrez-Xicotencatl, Mde. L. Association between presence of anti-Ras and anti-VPH16 E4/E7 antibodies and cervical intraepithelial lesions. Salud. Publica Mex. 2003, 45, 335-345.
69. Sentjens, R.; Basaras, M.; Simmonds, P.; Vrielink, H.; Reesink, H. HGV/GB virus C transmission by blood components in patients undergoing open-heart surgery. Transfusion 2003, 43, 1558-1562.
70. Srinivas, P. R.; Verma, M.; Zhao, Y.; Srivastava, S. Proteomics for cancer biomarker discovery. Clin. Chem. 2002, 48, 1160-1169.
71. Negm, R. S.; Verma, M.; Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 2002, 8, 288-293.
72. Petricoin, E. F.; Ardekani, A. M.; Hitt, B. A.; Levine, P. J.; Fusaro, V. A.; Steinberg, S. M.; Mills, G. B.; Simone, C.; Fishman, D. A.; Kohn, E. C.; Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
73. Jones, M. B.; Krutzsch, H.; Shu, H.; et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002, 2, 76-84.
74. Luo, X.; Carlson, K. A.; Wojna, V.; et al.. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology 2003, 60, 1931-1937.
75. Viard, M.; Blumenthal, R.; Raviv, Y. Improved separation of integral membrane proteins by continuous elution electrophoresis with simultaneous detergent exchange: application to the purification of the fusion protein of the human immunodeficiency virus type 1. Electrophoresis 2002, 23, 1659-1666.
76. Kim, Y. J.; Freas, A.; Fenselau, C. Analysis of viral glycoproteins by MALDI-TOF mass spectrometry. Anal. Chem. 2001, 73, 1544-1548.
77. Zhao, L.; Xu, S.; Peterson, C.; Kuroki, M.; Venge, P. Purification and characterization of a 95-kDa protein-carcinoembryonic antigen-related cell adhesion molecule 8-from normal human granulocytes. J. Immunol. Methods 2002, 270, 27-35.
78. Caputo, E.; Camarca, A.; Moharram, R.; Tornatore, P.; Thatcher, B.; Guardiola, J.; Martin, B. M. Structural study of GCDFP-15/ gp17 in disease versus physiological conditions using a proteomic approach. Biochemistry 2003, 42, 6169-6178.
79. Steen, H.; Kuster, B.; Mann, M. Quadrupole time-of-flight versus triple-quadrupole mass spectrometry for the determination of phosphopeptides by precursor ion scanning. J. Mass Spectrom. 2001, 36, 782-790.
80. Gineste, C.; Ho, L.; Pompl, P.; Blanchi, M.; Pasinetti, G. M. High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: effects of nimesulide. Drugs 2003, 63, 23-29.
81. Liotta, L. A.; Espina, V.; Mehta, A. I.; Calvert, V.; Rosenblatt, K.; Geho, D.; Munson, P. J.; Young, L.; Wulfkuhle, J.; Petricoin, E. F. 3rd Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003, 3, 317-325.
82. Sreekumar, A.; Chinnaiyan, A. M. Protein microarrays: a powerful tool to study cancer. Curr. Opin. Mol. Ther. 2002, 4, 587-593.
83. Miller, J. C., Zhou, H.; Kweke, J.; Cavallo, R.; Burke, J.; Butler, E. B.; The, B. S.; Haab, B. B. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003, 3, 56-63.
84. Lal, S. P.; Christopherson, R. I.; dos Remedios, C. G. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today 2002, 7, S143-149.
85. Krokhin, O.; Li, Y.; Andonov, A.; Flick, R.; Jones, S.; Stroeher, U.; Bastien, N.; Dasuri, K. V.; Cheng, K.; Simonsen, J. N.; Perreault, H.; Wilkins, J.; Ens, W.; Plummer, F.; Standing, K. G. Mass Spectrometric Characterization of Proteins from the SARS Virus: A Preliminary Report. Mol. Cell Proteomics 2003, 2, 346-356.
86. Brichory, F. M.; Misek, D. E.; Yim, A. M.; Krause, M. C.; Giordano, T. J. Beer DG, Hanash SM. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 9824-9829.
87. Albeniz Arbizu, E.; Barcena Marugan, R.; Oton Nieto, E.; Carrera Alonso, E.; Garcia Gonzalez, M.; Moreno Garcia, J.; de Vicente Lopez, E.; Nuno Vazquez-Garza, J.; Martin Davila, P. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results. Transplant Proc. 2003, 35, 1848-1849.
88. Blum, H. E. Molecular therapy and prevention of hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2003, 2, 11-22.
89. Hugle, T.; Cerny, A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 2003, 13, 361-371.
90. Sen, A.; Steele, R.; Ghosh, A. K.; Basu, A.; Ray, R.; Ray, R. B. Inhibition of hepatitis C virus protein expression by RNA interference. Virus Res. 2003, 96, 27-35.
91. Reiser, M.; Buggisch, P.; Grossmann, J.; Koop, K.; Wursthorn, K.; Schmiegel, W. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 2003, 15, 1299-1304.
92. Lee, S. K.; Dabney-Smith, C.; Hacker, D. L.; Bruce, B. D. Membrane activity of the southern cowpea mosaic virus coat protein: the role of basic amino acids, helix-forming potential, and lipid composition. Virology 2001, 291, 299-310.
93. Chavez, A.; Pujol, M.; Haro, I.; Alsina, M. A.; Cajal, Y. Membrane fusion by an RGD-containing sequence from the core protein VP3 of hepatitis A virus and the RGA-analogue: implications for viral infection. Biopolymers 2001, 58, 63-77.
94. Hayashi, K.; Chen, W. G.; Chen, Y. Y.; et al. Deletion of Epstein-Barr virus latent membrane protein 1 gene in United States and Brazilian Hodgkin's disease and reactive lymphoid tissue: high frequency of a 30-bp deletion. Hum. Pathol. 1997, 28, 1408-1414.
95. Belliot, G.; Laveran, H.; Monroe, S. S. Capsid protein composition of reference strains and wild isolates of human astroviruses. Virus Res. 1997, 49, 49-57.
96. Kushner, D. B.; Lindenbach, B. D.; Grdzelishvili, V. Z.; Noueiry, A. O.; Paul, S. M.; Ahlquist, P. Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 15764-1579.
97. Blanche, F.; Monegier, B.; Faucher, D.; Duchesne, M.; Audhuy, F.; Barbot, A.; Bouvier, S.; Daude, G.; Dubois, H.; Guillemin, T.; Maton, L. Polypeptide composition of an adenovirus type 5 used in cancer gene therapy. J. Chromatogr. A 2001, 921, 39-48.
98. Toda, T.; Sugimoto, M. Proteome analysis of Epstein-Barr virus-transformed B-lymphoblasts and the proteome database. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2003, 787, 197-206.
99. He, Q. Y.; Lau, G. K.; Zhou, Y.; Yuen, S. T.; Lin, M. C.; Kung, H. F.; Chiu, J. F. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics 2003, 3, 666-674.
100. Li, S. W.; Zhang, J.; He, Z. Q.; et al. [The study of aggregate of the ORF2 peptide of hepatitis E virus expressed in Escherichia coli]. Sheng Wu Gong ChengXue Bao 2002, 18, 463-467.
101. Ayers, M.; Siu, K.; Roberts, E.; Garvin, A. M.; Tellier, R. Characterization of hepatitis C virus quasispecies by matrix-assisted laser desorption ionization-time-of-flight (mass spectrometry) mutation detection. J. Clin. Microbiol. 2002, 40, 3455-3462.
102. Schneider, V. Symposium part 2: Should the Bethesda System terminology be used in diagnostic surgical pathology?: Counterpoint. Int. J. Gynecol. Pathol. 2003, 22, 13-17.
103. Kurata, A.; Katamine, S.; Fukuda, T.; et al. Production of a monoclonal antibody to a membrane antigen of human T-cell leukaemia virus (HTLV1/ATLV)-infected cell lines from a systemic lupus erythematosus (SLE) patient: serological analyses for HTLV1 infections in SLE patients. Clin. Exp. Immunol. 1985, 62, 65-74.
104. Croul, S.; Otte, J.; Khalili, K. Brain tumors and polyomaviruses. J Neurovirol. 2003, 9, 173-182.
105. Tognon, M.; Corallini, A.; Martini, F.; Negrini, M.; Barbanti-Brodano G. Oncogenic transformation by BK virus and association with human tumors. Oncogene 2003, 22, 5192-5200.
106. Khalili, K.; Del Valle, L.; Otte, J.; Weaver, M.; Gordon, J. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003, 22, 5181-5191.
107. Courville, P.; Simon, F.; Le Pessot, F.; Tallet, Y.; Debab, Y.; Metayer, J. Detection of HHV8 latent nuclear antigen by immunohistochemistry. A new tool for differentiating Kaposi's sarcoma from its mimics. Ann. Pathol. 2002, 22, 267-276.
108. Zhang, Y. J.; Wang, X. P.; Deng, J. H.; Salinas, R. A.; Oishi, N.; Gao, S. J. Suppression of oncogenic viral interferon regulatory factor (vIRF) of Kaposi's sarcoma-associated herpesvirus by ribozyme-mediated cleavage. Cancer Gene Ther. 2001, 8, 285-293.
109. Katano, H.; Iwasaki, T.; Baba, N.; Terai, M.; Mori, S.; Iwamoto, A.; Kurata, T.; Sata T. Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. J. Virol. 2000, 74, 3478-3485.